Health TrialsbyHealthPanel

Impact of Sarcopenia on Dyspnea in Patients With Asthma

ConditionsSarcopeniaAsthmaDyspneaDyspnea; AsthmaticCytokinesAdipokinesMyokineMuscle Disorder
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Clermont-Ferrand

About this trial

Dyspnea in asthma, is mainly due to airway obstruction but can be caused by several alternative diagnoses.

The impact of sarcopenia on dyspnea in patients with asthma is unknown. Sarcopenic asthma had a reduced physical activity and is associated with airway obstruction compared to non-sarcopenic asthma. In patients with obstructive pulmonary disease, sarcopenia is associated with shallow breathing and diverse sensory and affective components of exertional dyspnea .

The morbidity of sarcopenia is also increased by systemic inflammation and the production of inflammatory cytokines as found in inflammatory airway obstruction.

The investigators will investigate the prevalence and impact of sarcopenia in asthmatics patients. This will enable to better manage sarcopenia in asthmatic patients, understand its origins and personalize treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

Patient affiliated to a social security scheme.

Patient capable of giving free, informed, written and signed consent.

Asthmatic patients with a diagnosis made by a pulmonologist on GINA level 4 or 5 treatment

Disqualifiers

Patient under guardianship/trusteeship/supervision of justice

Pregnant or breast-feeding women

Unstable heart disease

Patients who have been smoking or have stopped smoking for less than 5 years,

Trial design

Design model

Single group

Treatments tested in this trial

  • muscle evaluation

    Diagnostic test

    The investigators will evaluate the muscle mass and muscle strenght for all patients included

  • Dosage

    Biological/Vaccine

    Evaluation of the cinetic of biomarkers during exercise

  • Cardiopulmonary exercise test

    Diagnostic test

    CPET

  • Questionnaire and Physical Exam

    Combination product

    Evaluating dyspnea, anxiety, sleep, physical activity, quality of life

Treatment groups

100 Participants
are divided into 1 treatment group
Group A: All the patient included in the studyExperimental treatment 4 interventions

Trial outcomes

Primary outcomes

1

Variation in the intensity of dyspnea during exercise mesured with Borg scale (0-10) according to the presence of sarcopenia

Recording of Borg's dyspnea score during exercise on a scale of 0 (no dyspnea) to 10 (major dyspnea)

Time frame
From baseline (at rest) to the end of the exercise

Secondary outcomes

1

Variation in exercise-induced release of biomarkers according to the presence of sarcopenia

Variation of cytokine as IL-1, IL-6, IL-8, IL-10 and TNF-alpha plasma concentrations (pg/mL) ; adipokines ; myokines

Time frame
at rest = baseline / right after the end of exercice / 45 minutes after the end of exercice
2

Difference in muscle mass (kg) on impedancemetry according to the presence of sarcopenia

Time frame
Baseline
3

Difference on maximum aerobic capacity (VO2 max in L/mn) , according to the presence of sarcopenia

Difference on physical activity

Time frame
immediately after the exercise test
4

Difference in fat mass (kg) on impedancemetry according to the presence of sarcopenia

Time frame
At baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Clermont-Ferrand

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: